OR WAIT null SECS
September 16, 2021
FDA and EMA will provide scientific advice to applicants concerning complex generic and hybrid products.
September 14, 2021
Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.
AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.
HUTCHMED’s amdizalisib (HMPL-689) received breakthrough therapy designation for the treatment of a subtype of non-Hodgkin’s lymphoma.
Both Marion Gruber and Phillip Krause, FDA officials, co-authored a document disputing the need for COVID-19 boosters for most people.
September 13, 2021
The memorandum of understanding between ABITEC and Luca AICell will work to advance ultra-high purity lipidic chemistries.
Boehringer Ingelheim and Twist Bioscience will use Twist’s antibody libraries to discover therapeutic antibody candidates.
September 10, 2021
Janssen’s Invega Hayfera is the first six-month injectable schizophrenia treatment approved by FDA.
Vector Laboratories has completed a $124 million cash buyout backed by Thompson Street Capital Partners and will begin an acquisition strategy to expand protein detection capabilities.
ABPI has announced that eight leaders from the patient and health charity sector have been chosen to join its new Patient Advisory Council.